International Clinical Trial: Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07458529) titled 'Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer' on March 4.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Seventh Medical Center of PLA General Hospital

Condition: Rectal Cancer, Adenocarcinoma Neoadjuvant Therapy Immunotherapy Probio-M9 Tislelizumab Randomized

Intervention: Combination Product: CRT+PD-1 inhibitor+Probio-M9

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: February 10...